• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Severe ICANS after CAR T-cell therapy and assessment of prevention with levetiracetam for seizure prophylaxis following CAR T-cell for DLBCL & PMBCL in Europe: a survey on behalf of the Cellular Therapy & Immunobiology Working Party (CTIWP) of the EBMT.

作者信息

Angelillo Piera, Alarcon Tomas Ana, Campodonico Edoardo, Novak Urban, Gabellier Ludovic, Blau Igor Wolfgang, Kwon Mi, Ram Ron, Forcade Edouard, Besley Caroline, Vucinic Vladan, Kröger Nicolaus, Corral Lucía López, Vydra Jan, Ferrari Silvia, von Tresckow Bastian, Rubio Marie Therese, Hernani Rafael, Sica Simona, Stölzel Friedrich, Rovira Montserrat, Wagner-Drouet Eva, Pérez-Simón Jose Antonio, Castilla-Llorente Cristina, Ferreri Andres J M, Hoogenboom Jorinde D, Sanchez Ortega Isabel, Malard Florent, Kuball Jürgen, Ruggeri Annalisa

机构信息

San Raffaele Scientific Institute, Milan, Italy.

Clinica Puerta de Hierro, Madrid, Spain.

出版信息

Bone Marrow Transplant. 2025 Jan;60(1):100-102. doi: 10.1038/s41409-024-02451-8. Epub 2024 Oct 25.

DOI:10.1038/s41409-024-02451-8
PMID:39455896
Abstract
摘要

相似文献

1
Severe ICANS after CAR T-cell therapy and assessment of prevention with levetiracetam for seizure prophylaxis following CAR T-cell for DLBCL & PMBCL in Europe: a survey on behalf of the Cellular Therapy & Immunobiology Working Party (CTIWP) of the EBMT.欧洲CAR T细胞治疗后严重免疫效应细胞相关神经毒性综合征（ICANS）及左乙拉西坦预防弥漫性大B细胞淋巴瘤（DLBCL）和原发性纵隔大B细胞淋巴瘤（PMBCL）患者CAR T细胞治疗后癫痫发作的评估：代表欧洲血液和骨髓移植协会（EBMT）细胞治疗与免疫生物学工作组（CTIWP）开展的一项调查
Bone Marrow Transplant. 2025 Jan;60(1):100-102. doi: 10.1038/s41409-024-02451-8. Epub 2024 Oct 25.
2
Choice of commercially available CAR-T cell products for r/r DLBCL & PMBCL in Europe: a survey on behalf of the cellular therapy & immunobiology working party (CTIWP) of the EBMT.欧洲复发/难治性弥漫性大B细胞淋巴瘤和原发性纵隔大B细胞淋巴瘤商用CAR-T细胞产品的选择：代表欧洲血液与骨髓移植协会细胞治疗与免疫生物学工作组（CTIWP）开展的一项调查
Bone Marrow Transplant. 2024 Nov;59(11):1631-1634. doi: 10.1038/s41409-024-02401-4. Epub 2024 Aug 27.
3
Diagnosis and Management of Secondary HLH/MAS Following HSCT and CAR-T Cell Therapy in Adults; A Review of the Literature and a Survey of Practice Within EBMT Centres on Behalf of the Autoimmune Diseases Working Party (ADWP) and Transplant Complications Working Party (TCWP).成人造血干细胞移植和嵌合抗原受体T细胞疗法后继发性噬血细胞性淋巴组织细胞增生症/巨噬细胞活化综合征的诊断与管理；文献综述及代表自身免疫性疾病工作组（ADWP）和移植并发症工作组（TCWP）对欧洲血液和骨髓移植协会（EBMT）中心的实践调查
Front Immunol. 2020 Mar 31;11:524. doi: 10.3389/fimmu.2020.00524. eCollection 2020.
4
Outcomes of CD19-Directed Chimeric Antigen Receptor T Cell Therapy for Transformed Nonfollicular Lymphoma.CD19 导向嵌合抗原受体 T 细胞疗法治疗转化型非滤泡性淋巴瘤的结果。
Transplant Cell Ther. 2023 Jun;29(6):349.e1-349.e8. doi: 10.1016/j.jtct.2023.02.021. Epub 2023 Mar 5.
5
The landscape of immune monitoring in CAR-T cell therapy: A comprehensive review and survey study by the Cellular Therapy and Immunobiology Working Party of the EBMT.嵌合抗原受体T细胞疗法中的免疫监测概况：欧洲血液与骨髓移植协会细胞治疗与免疫生物学工作组的综合综述及调查研究
Blood Rev. 2025 May;71:101272. doi: 10.1016/j.blre.2025.101272. Epub 2025 Feb 15.
6
Defining the impact of SARS-COV-2 on delivery of CAR T-cell therapy in Europe: a retrospective survey from the CTIWP of the EBMT.确定SARS-CoV-2对欧洲嵌合抗原受体T细胞疗法（CAR T细胞疗法）实施的影响：来自欧洲血液与骨髓移植协会细胞治疗工作小组（EBMT-CTIWP）的一项回顾性调查
Bone Marrow Transplant. 2022 Feb;57(2):299-301. doi: 10.1038/s41409-021-01483-8. Epub 2021 Nov 20.
7
The European Society for Blood and Marrow Transplantation (EBMT) roadmap and perspectives to improve nutritional care in patients undergoing hematopoietic stem cell transplantation on behalf of the Cellular Therapy and Immunobiology Working Party (CTIWP) and the Nurses Group (NG) of the EBMT.欧洲血液和骨髓移植学会（EBMT）改善造血干细胞移植患者营养护理的路线图和展望，代表细胞治疗和免疫生物学工作组（CTIWP）和 EBMT 的护士组（NG）。
Bone Marrow Transplant. 2023 Sep;58(9):965-972. doi: 10.1038/s41409-023-02018-z. Epub 2023 Jul 5.
8
An international survey on the management of patients receiving CAR T-cell therapy for haematological malignancies on behalf of the Chronic Malignancies Working Party of EBMT.代表 EBMT 慢性恶性肿瘤工作组的一项关于血液系统恶性肿瘤接受 CAR T 细胞治疗患者管理的国际调查。
Curr Res Transl Med. 2019 Aug;67(3):79-88. doi: 10.1016/j.retram.2019.05.002. Epub 2019 Jun 8.
9
Handling, processing and disposal of stem cell products in Europe: A survey by the cellular therapy and immunobiology working party of the European Society for Blood and Marrow Transplantation.欧洲间充质干细胞产品的处理、加工和处置：欧洲血液和骨髓移植学会细胞治疗和免疫生物学工作组的调查。
Cytotherapy. 2018 Mar;20(3):453-460. doi: 10.1016/j.jcyt.2017.12.005. Epub 2018 Jan 17.
10
Case report: Rapid resolution of grade IV ICANS after first line intrathecal chemotherapy with methotrexate, cytarabine and dexamethasone.病例报告：一线鞘内化疗（甲氨蝶呤、阿糖胞苷和地塞米松）后，IV 级 ICANS 迅速缓解。
Front Immunol. 2024 May 3;15:1380451. doi: 10.3389/fimmu.2024.1380451. eCollection 2024.

引用本文的文献

1
The Improving Outcomes in Relapsed-Refractory Diffuse Large B Cell Lymphoma: The Role of CAR T-Cell Therapy.改善复发难治性弥漫性大B细胞淋巴瘤的治疗效果：CAR T细胞疗法的作用
Curr Treat Options Oncol. 2025 Apr 28. doi: 10.1007/s11864-025-01305-9.

本文引用的文献

1
Current understanding and management of CAR T cell-associated toxicities.嵌合抗原受体 T 细胞相关毒性的现有认识和管理。
Nat Rev Clin Oncol. 2024 Jul;21(7):501-521. doi: 10.1038/s41571-024-00903-0. Epub 2024 May 20.
2
How I treat unique and difficult-to-manage cases of CAR T-cell therapy-associated neurotoxicity.我如何治疗 CAR T 细胞治疗相关神经毒性的独特且难以管理的病例。
Blood. 2023 May 18;141(20):2443-2451. doi: 10.1182/blood.2022017604.
3
Management of adults and children receiving CAR T-cell therapy: 2021 best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Association (EHA).
成人和儿童接受嵌合抗原受体 T 细胞（CAR T）疗法的管理：欧洲血液和骨髓移植学会（EBMT）、国际干细胞治疗认证委员会和 EBMT（JACIE）联合认证委员会以及欧洲血液学协会（EHA）的 2021 年最佳实践建议。
Ann Oncol. 2022 Mar;33(3):259-275. doi: 10.1016/j.annonc.2021.12.003. Epub 2021 Dec 16.
4
Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy.细胞因子释放综合征及癌症免疫治疗相关神经毒性
Nat Rev Immunol. 2022 Feb;22(2):85-96. doi: 10.1038/s41577-021-00547-6. Epub 2021 May 17.
5
Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study.西达基奥仑赛治疗复发或难治性大 B 细胞淋巴瘤患者的疗效和安全性（TRANSCEND NHL 001）：一项多中心无缝设计研究。
Lancet. 2020 Sep 19;396(10254):839-852. doi: 10.1016/S0140-6736(20)31366-0. Epub 2020 Sep 1.
6
KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma.KTE-X19 嵌合抗原受体 T 细胞疗法治疗复发或难治性套细胞淋巴瘤。
N Engl J Med. 2020 Apr 2;382(14):1331-1342. doi: 10.1056/NEJMoa1914347.
7
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma.阿基仑赛注射液嵌合抗原受体T细胞疗法治疗难治性大B细胞淋巴瘤
N Engl J Med. 2017 Dec 28;377(26):2531-2544. doi: 10.1056/NEJMoa1707447. Epub 2017 Dec 10.